With respect to this article, I noted that the company had obtained additional positive data from its Phase 1/2/3 CAMPSIITE study using RGX-121 for the treatment of these patients with MPS II.

ROCKVILLE, Md., Jan. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type ...

(RTTNews) - REGENXBIO Inc. (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for the treatment of Mucopolysaccharidosis II ...

The company is trading for roughly the cash on its balance sheet. The RGX-121 program is presently the furthest in development. REGENXBIO is pushing ahead with partner Nippon Shinyaku to ...

That partner, Japan’s Nippon Shinyaku, is handing over $110 million upfront to lead on the commercialization of two gene therapies—RGX-121 for Hunter syndrome and RGX-111 for Hurler syndrome.

ROCKVILLE, MD, USA I January 14, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) today announced a strategic partnership for the development and commercialization ...

In return for its investment, Nippon Shinyaku will gain access to two of Regenxbio’s gene therapies. The most mature of the assets is RGX-121, which is being tested for mucopolysaccharidosis type II, ...

VALORANT knife skins are perfect for sending a message, playing mind games with your opponents, and showing off to your teammates. They might come with a hefty price tag, but they’re worth the ...